VIRGINIA BEACH, Va.,
Jan. 10, 2017 /PRNewswire-USNewswire/
-- LifeNet Health's Dermacell acellular dermal matrix (ADM)
demonstrated statistically significant improvements compared to
AlloDerm Ready-To-Use (RTU) in both the incidence of Red Breast
Syndrome and time to drain removal among breast reconstruction
patients, according to the results of a study published by the
journal Plastic & Reconstructive Surgery.
The retrospective study, "Comparison of Different Acellular
Dermal Matrix (ADM) in Breast Reconstruction: The 50/50
Study1," compared clinical outcomes between Dermacell
and AlloDerm RTU in breast reconstruction — the most recent
empirical study to directly compare the two grafts. Fifty-eight
patients underwent reconstruction procedures using either Dermacell
(30 patients, 50 breasts) or AlloDerm RTU (28 patients, 50
breasts). The same surgeon performed all reconstructions.
Differences in the patients' average age, Body Mass Index, percent
of patients having neo-adjuvant/adjuvant chemotherapy or breast
irradiation, and numbers of therapeutic and prophylactic
mastectomies between the two patient groups was not statistically
significant.
Complications in both groups were recorded for 90 days post
reconstruction. The authors reported that, compared to the AlloDerm
group, patients in the Dermacell group showed statistically
significant improvement in the incidence of Red Breast Syndrome —
with zero cases reported among Dermacell recipients compared to 13
for AlloDerm RTU — and needed fewer days before drain removal (15.8
days versus 20.6). Additionally, the authors noted no significant
difference in terms of seroma, hematoma, delayed healing,
infection, flap necrosis, and explantation.
"The introduction of superior biomaterials like Dermacell
provides reconstructive surgeons with the tools needed to perform
cutting edge breast reconstruction in a safe and reproducible way,"
said Troy Pittman, MD, lead
investigator and author of the study. "The elimination of 'red
breast' and faster incorporation minimizes complications and
ultimately leads to faster recovery for the patients."
Dermacell, which is processed by LifeNet Health® and
distributed by NOVADAQ® Technologies, Inc., is a
technologically advanced ADM designed for post-mastectomy breast
reconstruction and for treatment of diabetic foot ulcers and
chronic wounds. These allograft implants are processed utilizing
Matracell® and Preservon®, two of LifeNet
Health's patented and validated technologies.
"LifeNet Health's processing technology is what differentiates
our allografts," said LifeNet Health President and CEO Rony Thomas. "The data in Dr. Pittman's study
clearly supports the fact that we have a technologically advanced,
superior process."
In Dec. 2014, NOVADAQ and LifeNet
Health forged a multi-year agreement making NOVADAQ the exclusive
worldwide distributor of Dermacell for wound management and breast
reconstruction.
About LifeNet Health
LifeNet Health helps save lives,
restore health, and give hope to thousands each year. It is the
world's most trusted provider of transplant solutions — from organ
procurement to bio-implants and cellular therapies — and a leader
in regenerative medicine, while always honoring the donors and
healthcare professionals who enable healing. For more information
about LifeNet Health, go to www.LifeNetHealth.org.
About NOVADAQ Technologies, Inc.
NOVADAQ (NASDAQ:NVDQ;
TSX:NDQ), enables physicians with point-of-care imaging solutions
that provide real-time clinically significant and actionable
information to improve care quality and lower healthcare costs.
Using NOVADAQ's SPY fluorescence imaging technology, physicians can
personalize therapy and achieve optimal results through the precise
visualization of blood flow in vessels, micro-vessels, tissue
perfusion and critical anatomical structures during the course of
treatment. SPY technology enables the delivery of personalized
therapies and the achievement of the optimal results for each
individual patient. More than 230 peer-reviewed publications
demonstrate that the use of SPY technology will reduce
post-procedure complication rates and the cost of care for a broad
variety of surgical treatments for cancer, cardiovascular diseases
and other conditions, helping to ensure that patients benefit from
the very best possible treatment and outcome. For more information,
please visit www.novadaq.com.
1 Pittman, Troy A., et al. "Comparison of Different
Acellular Dermal Matrix (ADM) in Breast Reconstruction: The 50/50
Study." Plastic and Reconstructive Surgery (2016).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/study-dermacell-demonstrates-superior-clinical-outcomes-compared-to-alloderm-in-breast-reconstruction-300388739.html
SOURCE LifeNet Health